Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13149192 | 1.00 | LSS (0.32) | LSS | |
| SCHEMBL3725896 | 1.00 | LSS (0.32) | LSS | |
| SCHEMBL14068268 | 1.00 | LSS (0.32) | LSS | |
| SCHEMBL16883359 | 0.81 | — | — | |
| SCHEMBL14709159 | 0.81 | — | — | |
| SCHEMBL19154152 | 0.81 | — | — | |
| SCHEMBL13644872 | 0.81 | — | — | |
| SCHEMBL15330939 | 0.79 | PGD (0.32) | — | |
| SCHEMBL14256138 | 0.79 | PGD (0.32) | — | |
| SCHEMBL12825900 | 0.79 | CYP3A4 (0.34) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5200516-A | Synthesis of sugars from substituted and unsubstituted arene diols | VIRGINIA TECH INTELLECTUAL PROPERTIES (US) | 1993-04-06 | — | — | US | claimed |
| WO-1991012257-A2 | SYNTHESIS OF SUGARS AND AMINO ACIDS FROM SUBSTITUTED AND UNSUBSTITUTED ARENE DIOLS | GENENCOR INTERNATIONAL, INC. (US) | 1991-08-22 | — | — | WO | claimed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| WO-2013158746-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-1991012257-A2 | SYNTHESIS OF SUGARS AND AMINO ACIDS FROM SUBSTITUTED AND UNSUBSTITUTED ARENE DIOLS | GENENCOR INTERNATIONAL, INC. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | LSS 1062/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | LSS 1062/4885 |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | LSS 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.